A Study of DB-1311 in Advanced/Metastatic Solid Tumors is a research trial that tests a new drug, DB-1311, on people with advanced solid tumors that have spread or cannot be surgically removed. The goal is to see if the drug is safe and how well it works. This study is in Phase 1/2a, which means it's early in the testing process. In Phase 1, different doses of the drug are tested to find the best amount to give. Phase 2a tests the chosen dose in more people to check safety and effectiveness.

Participants must be adults with tumors that have worsened after typical treatments. They need to be healthy enough to join and agree to follow study rules. Some people cannot join, such as those with heart problems or certain infections.

• The study requires multiple visits to the clinic.
• Participants may receive DB-1311 alone.
• There may be risks like side effects, which will be monitored.

This study helps researchers understand if DB-1311 can be a new treatment option for people with advanced tumors. Participants contribute to important cancer research.